Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2017 | Combining FLT3 and SYK inhibition for AML

Mark Levis • 9 Dec 2017
ASH 2017
Acute Myeloid Leukemia TAK-659

TAK-659 is a novel FLT3 inhibitor in the initial trial stages for the treatment of acute myeloid leukemia (AML). Interestingly, TAK-659 also inhibits SYK, a target that is more common in the treatment of B-cell malignancies. In this interview, Mark Levis, MD, PhD, of Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses the pharmacokinetics and promising preliminary results of the Phase I trial of this agent (NCT02323113) in patients with relapsed or refractory AML. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.

More from Mark Levis

1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
1:03
Personalizing AML treatment by targeting MRD mutations
Mark Levis • 10 Dec 2023
2:00
FLT3-ITD-specific MRD predicts outcomes of chemotherapy in AML
Mark Levis • 10 Dec 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
2:22
Haplo-SCT for older patients with AML/HR-MDS: should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals